| Company Name | Date | Time | Location | Session Title |
| Ultragenyx Pharmaceutical | 27 – May | 13:30-14:45 | Marie Curie Hall Forum 1 | Update on the Management of Patients with Homozygous Familial Hypercholesterolaemia (HoFH) More details |
| New Amsterdam Pharma / Menarini | 27 – May | 13:30-14:45 | Claude Bernard Hall Forum 3 | Role of CETP inhibitors in cardiovascular risk reduction: Lessons from the past and the road to the future More details |
| Novartis / Medscape | 27 – May | 13:30-14:15 | René Leriche Hall Forum 2 | Lp(a): The Hidden Heartbreaker Redefining Cardiovascular Health More details |
| MSD | 28 – May | 7:30-8:15 | Marie Curie Hall Forum 1 | Are patients a getting to their lipid goals? More details |
| Novo Nordisk | 28 – May | 13:45-14:30 | Marie Curie Hall Forum 1 | Inflammation: The next frontier in ASCVD care More details |
| Daiichi Sankyo | 28 – May | 13:45-14:30 | René Leriche Hall Forum 2 | HerHeart Symposium: Navigating LDL-C Management for Optimal Cardiovascular Health in Women More details |
| Novartis | 28 – May | 14:35-15:35 | Claude Bernard Hall Forum 3 | Stay committed to your goal: Sustained LDL-C reduction in the long-term and real-world More details |
| Amarin | 28 – May | 14:45-15:30 | Marie Curie Hall Forum 1 | Beyond LDL-c : Residual risk and Elevated triglycerides More details |
#EASCongress2024
Congress secretariat
Rue François-Versonnex 7
1207 Geneva, Switzerland
+41 22 908 0488
eas2024@kenes.com